NCT00663702

Phase IIIB Switching From Intravenous to Subcutaneous Study

A Phase 3B Multi-center Open-Label Study to Evaluate the Safety of Abatacept in Subjects Who Switch From Intravenous to Subcutaneous Abatacept Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether switching to subcutaneous administration of abatacept will be safe in participants with rheumatoid arthritis who previously received long-term therapy with intravenous abatacept

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	Abatacept	Subcutaneous injection, 125 mg/mL, once weekly, 48 months

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-12-01
• Completion: 2012-01-01
• First posted: 2008-04-22
• Last updated: 2015-03-09
• Results posted: 2012-03-26

Locations

30 sites across 3 countries: United States, Canada, Mexico